TECX vs TNGX: fair value comparison
Tectonic Therapeutic, Inc. and Tango Therapeutics, Inc. · Updated 2026-10-19
TECX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. TNGX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TECX currently ranks higher by quality score.
| TECX | TNGX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $20.65 | $22.04 |
| 12-month range | $16.44–$37.93 | $7.50–$32.90 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #271 of 301 Healthcare | #272 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: TECX fair value analysis · TNGX fair value analysis